KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$5.9 million.

  • Recursion Pharmaceuticals' Change in Account Payables fell 289.29% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 154.24%. This contributed to the annual value of $6.4 million for FY2024, which is 751.98% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Change in Account Payables of -$5.9 million as of Q3 2025, which was down 21.77% from -$4.8 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Change in Account Payables ranged from a high of $8.1 million in Q4 2024 and a low of -$5.9 million during Q3 2025.
  • Its 3-year average for Change in Account Payables is -$144,273, with a median of -$339,000 in 2023.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Change in Account Payables skyrocketed by 5,790.91% in 2021 and then tumbled by 1,488.73% in 2022.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Change in Account Payables stood at -$3.5 million in 2021, then spiked by 119.82% to $695,000 in 2022, then plummeted by 145.61% to -$317,000 in 2023, then spiked by 2,662.15% to $8.1 million in 2024, then crashed by 289.29% to -$5.9 million in 2025.
  • Its last three reported values are -$5.9 million in Q3 2025, -$4.8 million for Q2 2025, and $3.7 million during Q1 2025.